Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS
Tarsus Pharmaceuticals — Investor Presentation (January 2025)
20 slides from Tarsus Pharmaceuticals's investor presentation, January 2025
Slide 1: The Future of Eye Care Begins Here
The Future of Eye Care Begins Here January 2025 Matt, an XDEMVY® Patient
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These include statements regarding the potential commercial success
Slide 3: Bobby Azamian, MD, PhD, Chief Executive Officer and Chairman
BOBBY AZAMIAN, MD, PhD Chief Executive Officer And Chairman 3 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 4: Tarsus: The Next Leader in Eye Care
Tarsus The Next Leader in Eye Care Proven Blueprint XDEMVY® Ocular Rosacea For Creating Accelerating Toward A New Potentially New Categories Potential Blockbuster Status Transformational Opportunity • Expert leadership team with an • The first and only FDA-approved • Another impactful eye disease ex
Slide 5: XDEMVY: Accelerating Toward Potential Blockbuster Status
XDEMVY® Accelerating Toward Potential Blockbuster Status 5 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 6: Demodex Blepharitis: A Pervasive and Damaging Eyelid Disease
Demodex Blepharitis (DB): A Pervasive and Damaging Eyelid Disease Corneal manifestations3,4 The result of an infestation Easily diagnosed during Potential for serious of Demodex mites, DB can a routine eye exam clinical implications cause eyelid inflammation, through the identification if left untre
Slide 7: XDEMVY Launch YTD Q3 2024
XDEMVY Launch YTD Q3 2024 Driving One of the Fastest Growing Categories in Eye Care >104K Bottles Delivered to Patients >13K ECPs Have Prescribed XDEMVY >80% Commercial & Medicare Lives Covered >$113M Net Product Sales In Just One Year, XDEMVY has Become One of the Best Launches in Eye Care Abby, an
Slide 8: Demodex Blepharitis: A Multi-Billion-Dollar Potential Opportunity
Demodex Blepharitis A Multi-Billion-Dollar Potential Opportunity 1.5M DB Patients Already diagnosed & seeking treatment 1,2 1.5M MGD Patients With DB 1, 2, 3 1.2M Dry Eye Rx Patients With DB 1, 3, 4, 5 2.2M Cataract Patients With DB 1, 3, 6 2.3M Contact Lens Patients With DB 1, 3, 7 ~9.0M Patients P
Slide 9: XDEMVY: First Pharmacologic Treatment to Demonstrate Improvements in MGD
XDEMVY: First Pharmacologic Treatment To Demonstrate Groundbreaking Improvements in MGD and Patient Symptoms in DB Patients Combined data1 in patients with DB and MGD Improvement in Objective Improvements in demonstrated statistically significant and Measures of Meibomian Patient Symptoms – clinical
Slide 10: Fully Deployed Sales Force Propelling Continued Growth
Fully Deployed Sales Force Propelling Continued Growth Driving Depth of Adoption Meaningful Increase in ECPs Writing Monthly Weekly Daily Continued Evidence Ease of Access Optimized Sales Force Generation >80% of Commercial and Deepening utilization across Seminal MGD data and Medicare covered lives
Slide 11: Making XDEMVY a Household Name
Making XDEMVY a Household Name Direct-To-Consumer Campaign Driving Patients to ECPs 11 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 12: Ocular Rosacea
OCULAR ROSACEA The Next Potentially Transformational Category in Eye Care 12 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 13: The Next Impactful Area of Unmet Need
The Next Impactful Area of Unmet Need Ocular Rosacea Demodex Blepharitis (DB) Ocular Rosacea (OR) • Caused by Demodex mites • Caused by Demodex mites • Eyelid inflammation, redness, irritation, • Eye and eyelid inflammation and redness, collarettes prominent and visible blood vessels • Quick and sim
Slide 14: Ocular Rosacea: Another Clear, Large and Underserved Patient Population
Ocular Rosacea Another Clear, Large and Underserved Patient Population ~15-18M People Affected in the US1 >50% Caused by Demodex Mites1 0 FDA-Approved Treatments Opportunity to Leverage Our Proven Blueprint 1. Source on file 14 | © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 15: Potential to Pioneer the Standard of Care for Ocular Rosacea
TP-04 Potential to Pioneer the Standard of Care for Ocular Rosacea Targets Root Cause of Disease Demodex mites Uniquely Tailored Sterile Ophthalmic Gel Specifically designed to be applied to the eyelid and surrounding tissue Best-in-Class Molecule Lotilaner - poised to deliver another transformative
Slide 16: Clear FDA Guidance and a Defined Path Forward
Clear FDA Guidance and a Defined Path Forward Plans to initiate Phase 2 in 2H 2025 with focus on 1 objective measures of disease – reduction in visible blood vessels and redness 2 Proof-of-concept results expected next year Regulatory path that leverages blueprint for 3 success and proven commercial
Slide 17: The Tarsus Opportunity is Real
The Tarsus Opportunity is Real XDEMVY Net Sales XDEMVY ($ in millions) $40.8 $48.1 On-track to potentially be $24.7 $13.1 one of the best launches in eye care Q4 2023 Q1 2024 Q2 2024 Q3 2024 XDEMVY Bottles ECPs Prescribing XDEMVY Delivered to Patients (in thousands)1 (in thousands) 37.0 41.4 11 13 2
Slide 18: Upcoming Potential Value Driving Catalysts
Upcoming Potential Value Driving Catalysts Greater U.S. Europe Japan China* TP-04 for Ocular Rosacea: XDEMVY for DB: TP-03 for DB: TP-03 for DB: Plans to initiate Ph 2 study in 2H 2025 On-track for potential regulatory Initial results from a prevalence New Drug Application accepted TP-05 for Lyme ap
Slide 19: Tarsus: The Next Leader in Eye Care
Tarsus The Next Leader in Eye Care Proven Blueprint XDEMVY® Ocular Rosacea For Creating Accelerating Toward A New Potentially New Categories Blockbuster Status Transformational Opportunity • Expert leadership team with an • The first and only FDA-approved • Another impactful eye disease expansive ra
Slide 20: Thank You
Thank You Sulma, an XDEMVY® Patient
Tarsus Pharmaceuticals — Investor Presentation (January 2025) on 6ix